Amgen loses $400 million antitrust battle to Regeneron
And more biotech news brought to you by The Readout.
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Morning! Today we start with some breaking newss: Novo Nordisk’s CEO is stepping down. We also discuss a new, tailored CRISPR treatment for an infant with a deadly disease, how Amgen owes Regeneron more than $400 million now, and more.
